<DOC>
	<DOC>NCT00122382</DOC>
	<brief_summary>This is a world wide study to evaluate the remission and joint damage in subjects treated with abatacept in addition to methotrexate versus subjects who receive methotrexate along with a placebo.</brief_summary>
	<brief_title>Remission and Joint Damage Progression in Early Rheumatoid Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Rheumatoid</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Abatacept</mesh_term>
	<criteria>Diagnosis of rheumatoid arthritis (RA) &lt;=2 years; MTX naive or &lt;=10 mg/wk for &lt;=3 weeks. No dose within 3 months prior to informed consent. CReactive Protein (CRP) &gt;= 4.5 mg/L (after amendment) Rheumatoid factor or anticyclic citrullinated peptide antibody (antiCCP) positive Tender joints &gt;=12 and swollen joints &gt;=10 Women and men who are not willing to use birth control Diagnosed with other rheumatic disease History of cancer within 5 years Active tuberculosis Treatment with another investigation drug within 28 days Active bacterial or viral infection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2010</verification_date>
	<keyword>abatacept, methotrexate, erosive RA</keyword>
</DOC>